PNEUMOCOCCAL VACCINES MARKET ANALYSIS

Pneumococcal Vaccines Market, By Vaccine Type (Pneumococcal Conjugate Vaccines (PCVs) (PCV13 (Prevnar 13/Prevenar 13), PCV10 (Synflorix), PCV7 (Prevnar/Prevenar)) and Pneumococcal Polysaccharide Vaccines (PPVs) (PPSV23 (Pneumovax 23), PPSV14 (Pneumo 14)), By Target Population (Adults (≥ 65 years), Children (< 5 years), High-Risk Adults (18-64 years)), By Route of Administration (Intramuscular, Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In June 2024, Merck’s CAPVAXIVE (21-valent pneumococcal conjugate vaccine) was approved by U.S. FDA for preventing invasive pneumococcal disease and pneumonia in adults 18 and older. It targets serotypes responsible for most IPD cases in older adults and showed strong immune responses in clinical trials.
In April 2024, Merck announced the results of the STRIDE-10 phase 3 clinical trial for its investigational 21-valent pneumococcal conjugate vaccine designed for adults
In March 2024, Vaxcyte completed enrollment for its phase-2 clinical trial assessing the 24-valent pneumococcal conjugate vaccine candidate VAX-24, aimed at combating invasive pneumococcal disease (IPD) in children
In January 2024, Pfizer Inc. received marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC)
In October 2023, Vaxcyte, Inc. entered into a new commercial manufacturing agreement with Lonza, aiming to expand its production capacity for its pneumococcal conjugate vaccine candidates